8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 6, 2026·SEC
Material company update
Mar 30, 2026·SEC
Unicycive Therapeutics, Inc.(UNCY)Earnings, Financials & Key Ratios
UNCY•NASDAQ
Price updated Jun 19, 2026
AboutUnicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.Show more
- Revenue$0
- EBITDA-$29M+8.7%
- Net Income-$27M+27.7%
- EPS (Diluted)-1.67+70.2%
- ROE-141.14%+93.0%
UNCY Key Insights
Unicycive Therapeutics, Inc. (UNCY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 60.3% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
- ✗Expensive at 36.0x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when UNCY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
UNCY Price & Volume
Unicycive Therapeutics, Inc. (UNCY) stock price & volume — 10-year historical chart
Loading chart...
UNCY Growth Metrics
Unicycive Therapeutics, Inc. (UNCY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-162.89%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM45.05%
Return on Capital
10 Years-508.93%
5 Years-508.93%
3 Years-841.98%
Last Year-156.4%
UNCY Recent Earnings
Unicycive Therapeutics, Inc. (UNCY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.54-17.7%
$0.46
Rev
—
$11M
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.32+36.6%
$0.50
Rev
—
$517,000
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.39+33.9%
$0.59
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.52+25.7%
$0.70
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.54vs $0.46-17.7% | —vs $11M |
| Q2 2026 | Mar 30, 2026 | $0.32vs $0.50+36.6% | —vs $517,000 |
| Q4 2025 | Nov 12, 2025 | $0.39vs $0.59+33.9% | — |
| Q3 2025 | Aug 14, 2025 | $0.52vs $0.70+25.7% | — |
Based on last 12 quarters of dataView full earnings history →
UNCY Peer Comparison
Unicycive Therapeutics, Inc. (UNCY) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 CYCN | 13.86M | 3.20 | -2.94 | 3.7% | -264.73% | -62.1% | ||
 RMTI | 25.26M | 0.64 | -4.27 | -31.76% | -9.25% | -45.88% | 0.34 | |
 LPCN | 12.69M | 2.33 | -1.38 | -82.35% | -5.71% | -66.69% | ||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 VKTX | 3.52B | 30.38 | -9.52 | -71.31% | 0.00 | |||
 DVAX | 1.82B | 15.50 | 77.50 | 19.36% | -13.13% | -8.13% | 0.43 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 |
Compare UNCY vs Peers
Unicycive Therapeutics, Inc. (UNCY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
UNCY Income Statement
Unicycive Therapeutics, Inc. (UNCY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 951K | 675K | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | -29.02% | -100% | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 572K | 211K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 951K▲ 0% | 675K▼ 29.0% | 0▼ 100.0% | -572K▲ 0% | -211K▲ 0% |
Gross Margin % | - | - | - | - | 100% | 100% | - | - | - |
Gross Profit Growth % | - | - | - | - | - | -29.02% | -100% | - | - |
Operating Expenses | 952K | 1.96M | 2.02M | 8.98M | 19M | 21.45M | 32.12M | 28.95M | 29.75M |
OpEx % of Revenue | - | - | - | - | 1998.21% | 3177.63% | - | - | - |
Selling, General & Admin | 608K | 1.17M | 1M | 2.9M | 6.57M | 8.55M | 12.1M | 20.4M | 21.39M |
SG&A % of Revenue | - | - | - | - | 690.54% | 1266.22% | - | - | - |
Research & Development | 344K | 795K | 1.01M | 6.08M | 12.44M | 12.9M | 20.01M | 9.12M | 8.57M |
R&D % of Revenue | - | - | - | - | 1307.68% | 1911.41% | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -572K | -211K |
Operating Income | -952K▲ 0% | -1.96M▼ 106.2% | -2.02M▼ 2.9% | -8.98M▼ 344.4% | -18.05M▼ 101.1% | -20.77M▼ 15.1% | -32.12M▼ 54.6% | -29.52M▲ 8.1% | -29.97M▲ 0% |
Operating Margin % | - | - | - | - | -1898.21% | -3077.63% | - | - | - |
Operating Income Growth % | - | -106.2% | -2.9% | -344.41% | -101.09% | -15.08% | -54.6% | 8.1% | - |
EBITDA | 0 | 0 | 0 | -8.96M | -17.89M | -20.49M | -31.69M | -28.95M | -29.32M |
EBITDA Margin % | - | - | - | - | -1881.28% | -3035.56% | - | - | - |
EBITDA Growth % | - | - | - | - | -99.59% | -14.53% | -54.66% | 8.66% | 4.31% |
D&A (Non-Cash Add-back) | 952K | 1.96M | 2.02M | 13K | 161K | 284K | 428K | 572K | 648K |
EBIT | -952K | -2.03M | -2.02M | -9.39M | -18.05M | -30.46M | -36.66M | -26.48M | -35.51M |
Net Interest Income | 0 | 0 | 0 | -628K | -6K | 533K | 1.19M | 941K | 1.12M |
Interest Income | 168K | 139K | 244K | 0 | 0 | 615K | 1.26M | 1.01M | 1.18M |
Interest Expense | 0 | 139K | 244K | 628K | 6K | 82K | 71K | 71K | 55K |
Other Income/Expense | -168K | -202K | -244K | -1.04M | -6K | -9.77M | -4.61M | 2.96M | -9.98M |
Pretax Income | -1.12M▲ 0% | -2.17M▼ 93.3% | -2.26M▼ 4.6% | -10.02M▼ 342.4% | -18.06M▼ 80.3% | -30.54M▼ 69.1% | -36.73M▼ 20.2% | -26.55M▲ 27.7% | -39.95M▲ 0% |
Pretax Margin % | - | - | - | - | -1898.84% | -4525.04% | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -1.12M▲ 0% | -2.3M▼ 105.7% | -2.51M▼ 8.9% | -10.02M▼ 299.4% | -18.06M▼ 80.3% | -30.54M▼ 69.1% | -36.73M▼ 20.2% | -26.55M▲ 27.7% | -39.95M▲ 0% |
Net Margin % | - | - | - | - | -1898.84% | -4525.04% | - | - | - |
Net Income Growth % | - | -105.71% | -8.85% | -299.4% | -80.27% | -69.14% | -20.25% | 27.7% | -162.89% |
Net Income (Continuing) | -1.12M | -2.17M | -2.26M | -10.02M | -18.06M | -30.54M | -36.73M | -26.55M | -39.95M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.14▲ 0% | -0.27▼ 92.9% | -0.16▲ 40.7% | -8.60▼ 5275.0% | -1.20▲ 86.0% | -1.28▼ 6.7% | -5.60▼ 337.5% | -1.67▲ 70.2% | -0.17▲ 0% |
EPS Growth % | - | -92.86% | 40.74% | -5275% | 86.05% | -6.67% | -337.5% | 70.18% | 45.05% |
EPS (Basic) | -0.14 | -0.27 | -0.16 | -8.60 | -1.20 | -1.28 | -5.60 | -1.67 | - |
Diluted Shares Outstanding | 794.32K | 847.15K | 1.52M | 1.17M | 1.51M | 2.45M | 6.7M | 158.87M | 239.08M |
Basic Shares Outstanding | 794.32K | 842.5K | 1.52M | 1.17M | 1.51M | 2.45M | 6.7M | 158.87M | 239.08M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
UNCY Balance Sheet
Unicycive Therapeutics, Inc. (UNCY) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 29K | 19K | 204K | 18.41M | 2.64M | 13.4M | 30.95M | 48.96M | 63.55M |
Cash & Short-Term Investments | 25K | 15K | 0 | 16.58M | 455K | 9.7M | 26.14M | 41.27M | 54.59M |
Cash Only | 25K | 15K | 0 | 16.58M | 455K | 9.7M | 26.14M | 29.2M | 37.37M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.07M | 17.21M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 4K | 204K | 126K | 159K | 325K | 939K | 7.69M | 8.96M |
Total Non-Current Assets | 0 | 0 | 200K | 333K | 174K | 792K | 720K | 174K | 861K |
Property, Plant & Equipment | 0 | 0 | 0 | 333K | 174K | 792K | 720K | 174K | 861K |
Fixed Asset Turnover | - | - | - | - | 5.47x | 0.85x | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 200K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 29K▲ 0% | 19K▼ 34.5% | 204K▲ 973.7% | 18.74M▲ 9088.2% | 2.82M▼ 85.0% | 14.19M▲ 403.6% | 31.67M▲ 123.2% | 49.13M▲ 55.2% | 64.41M▲ 0% |
Asset Turnover | - | - | - | - | 0.34x | 0.05x | - | - | 0.00x |
Asset Growth % | - | -34.48% | 973.68% | 9088.24% | -84.97% | 403.58% | 123.16% | 55.16% | 183.92% |
Total Current Liabilities | 1.24M | 903K | 2.88M | 2.1M | 3.28M | 17.53M | 24.12M | 18.94M | 26.48M |
Accounts Payable | 60K | 322K | 184K | 742K | 846K | 821K | 966K | 383K | 1.14M |
Days Payables Outstanding | - | - | - | - | - | - | - | 244.4 | 1.38K |
Short-Term Debt | 1.05M | 460K | 2.51M | 29K | 46K | 18K | 92K | 117K | 598K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | -29K | 0 | 13.13M | 18.94M | 18.44M | 24.75M |
Current Ratio | 0.02x | 0.02x | 0.07x | 8.75x | 0.81x | 0.76x | 1.28x | 2.59x | 2.40x |
Quick Ratio | 0.02x | 0.02x | 0.07x | 8.75x | 0.81x | 0.76x | 1.28x | 2.59x | 2.40x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 155K | 0 | 466K | 117K | 0 | 217K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 217K |
Capital Lease Obligations | 0 | 0 | 0 | 155K | 0 | 466K | 117K | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.24M | 903K | 2.88M | 2.26M | 3.28M | 18M | 24.24M | 18.94M | 26.7M |
Total Debt | 1.05M | 460K | 2.51M | 335K | 201K | 811K | 773K | 117K | 815K |
Net Debt | 1.02M | 445K | 2.51M | -16.24M | -254K | -8.89M | -25.37M | -29.08M | -36.56M |
Debt / Equity | - | - | - | 0.02x | - | - | 0.10x | 0.00x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 1.25x |
Interest Coverage | - | -14.58x | -8.28x | -14.95x | -3008.67x | -371.49x | -516.31x | -373.01x | -645.60x |
Total Equity | -1.21M▲ 0% | -884K▲ 26.7% | -2.67M▼ 202.1% | 16.48M▲ 717.1% | -466K▼ 102.8% | -3.81M▼ 717.4% | 7.43M▲ 295.1% | 30.2M▲ 306.4% | 37.7M▲ 0% |
Equity Growth % | - | 26.7% | -202.15% | 717.15% | -102.83% | -717.38% | 295.09% | 306.37% | 527.89% |
Book Value per Share | -1.52 | -1.04 | -1.75 | 14.12 | -0.31 | -1.55 | 1.11 | 0.19 | 0.16 |
Total Shareholders' Equity | -1.21M | -884K | -2.67M | 16.48M | -466K | -3.81M | 7.43M | 30.2M | 37.7M |
Common Stock | 34K | 8K | 9K | 15K | 15K | 35K | 114K | 22K | 25K |
Retained Earnings | -1.49M | -3.66M | -5.92M | -15.94M | -34M | -64.54M | -101.27M | -127.83M | -140.65M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1K | 6K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
UNCY Cash Flow Statement
Unicycive Therapeutics, Inc. (UNCY) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -775K | -1.18M | -1.46M | -5.77M | -15.65M | -18.28M | -28.57M | -31.32M | -28.66M |
Operating CF Margin % | - | - | - | - | -1645.74% | -2708.59% | - | - | - |
Operating CF Growth % | - | -51.74% | -24.06% | -295.27% | -171.39% | -16.82% | -56.29% | -9.6% | 9.55% |
Net Income | -1.12M | -2.17M | -2.26M | -10.02M | -18.06M | -30.54M | -36.73M | -26.55M | -39.95M |
Depreciation & Amortization | 0 | 0 | 0 | 13K | 161K | 284K | 428K | 572K | 648K |
Stock-Based Compensation | 0 | 24K | 232K | 966K | 1.05M | 1.77M | 2.35M | 2.64M | 2.1M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 308K | 660K | 739K | 3.38M | 21K | 10.3M | 5.8M | -2.02M | 11.87M |
Working Capital Changes | 6K | 305K | -166K | -105K | 1.18M | -93K | -427K | -5.95M | -3.32M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 31K | 308K | -68K | 1.24M | 1.27M | 1.28M | 790K | -2.5M | -1.01M |
Cash from Investing | 0 | 0 | 0 | -29K | -2K | -12K | -72K | -12.1M | -17.23M |
Capital Expenditures | 0 | 0 | 0 | -29K | -2K | -12K | -72K | -24K | -16K |
CapEx % of Revenue | - | - | - | - | 0.21% | 1.78% | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -10K |
Cash from Financing | 800K | 1.17M | 1.44M | 22.38M | -471K | 27.54M | 45.09M | 46.47M | 63.49M |
Debt Issued (Net) | 0 | 0 | 1.42M | -15K | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 1.17M | 141K | 22.27M | 11K | 30.19M | 50.68M | 48.08M | 61.96M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | -1.09M | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 800K | 0 | -117K | 119K | -482K | -2.65M | -4.5M | -1.61M | 1.53M |
Net Change in Cash | 25K▲ 0% | -10K▼ 140.0% | -15K▼ 50.0% | 16.58M▲ 110626.7% | -16.12M▼ 197.3% | 9.25M▲ 157.3% | 16.44M▲ 77.8% | 3.06M▼ 81.4% | 17.6M▲ 0% |
Free Cash Flow | -775K▲ 0% | -1.18M▼ 51.7% | -1.46M▼ 24.1% | -5.8M▼ 297.3% | -15.65M▼ 170.1% | -18.3M▼ 16.9% | -28.65M▼ 56.6% | -31.34M▼ 9.4% | -28.67M▲ 0% |
FCF Margin % | - | - | - | - | -1645.95% | -2710.37% | - | - | - |
FCF Growth % | - | -51.74% | -24.06% | -297.26% | -170.07% | -16.88% | -56.58% | -9.4% | 7.82% |
FCF per Share | -0.98 | -1.39 | -0.96 | -4.96 | -10.40 | -7.46 | -4.28 | -0.20 | -0.12 |
FCF Conversion (FCF/Net Income) | 0.69x | 0.51x | 0.58x | 0.58x | 0.87x | 0.60x | 0.78x | 1.18x | 0.72x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 24K | 0 | 0 | 3K |
Taxes Paid | 0 | 2K | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
UNCY Key Ratios
Unicycive Therapeutics, Inc. (UNCY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -145.04% | -225.47% | - | -2028.11% | -141.14% | -131.18% |
Return on Invested Capital (ROIC) | - | - | -16223.49% | - | - | - | - | 1142.58% |
Gross Margin | - | - | - | 100% | 100% | - | - | - |
Net Margin | - | - | - | -1898.84% | -4525.04% | - | - | - |
Debt / Equity | - | - | 0.02x | - | - | 0.10x | 0.00x | 0.02x |
Interest Coverage | -14.58x | -8.28x | -14.95x | -3008.67x | -371.49x | -516.31x | -373.01x | -645.60x |
FCF Conversion | 0.51x | 0.58x | 0.58x | 0.87x | 0.60x | 0.78x | 1.18x | 0.72x |
Revenue Growth | - | - | - | - | -29.02% | -100% | - | - |
Related:UNCY Dividend History·UNCY Revenue History·UNCY Price History·UNCY P/E History·UNCY Financial Ratios·UNCY Institutional Holders
UNCY SEC Filings & Documents
Unicycive Therapeutics, Inc. (UNCY) SEC filings — annual & quarterly reports (10-K, 10-Q)
UNCY Frequently Asked Questions
Unicycive Therapeutics, Inc. (UNCY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Unicycive Therapeutics, Inc. (UNCY) grew revenue by 0.0% over the past year. Growth has been modest.
Unicycive Therapeutics, Inc. (UNCY) reported a net loss of $39.9M for fiscal year 2025.
Dividend & Returns
Unicycive Therapeutics, Inc. (UNCY) has a return on equity (ROE) of -141.1%. Negative ROE indicates the company is unprofitable.
Unicycive Therapeutics, Inc. (UNCY) had negative free cash flow of $28.7M in fiscal year 2025, likely due to heavy capital investments.